A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

(2013) Dana E. Rathkopf et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

(2013) Michel D. Wissing et al.   FASEB JOURNAL

Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas

(2011) Alcides Chaux et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

(2011) W. P. Yong et al.   ANNALS OF ONCOLOGY

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

(2011) A R A Razak et al.   BRITISH JOURNAL OF CANCER

PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

(2011) T. L. Lotan et al.   CLINICAL CANCER RESEARCH

PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications

(2011) Maisa Yoshimoto et al.   GENES CHROMOSOMES & CANCER

Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile

(2011) Haishan Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

(2010) Dana Rathkopf et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The role of histone deacetylases in prostate cancer

(2010) Ata Abbas et al.   Epigenetics

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

(2010) V. Novotny-Diermayr et al.   MOLECULAR CANCER THERAPEUTICS

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

(2009) L. R. Molife et al.   ANNALS OF ONCOLOGY

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

(2009) P N Munster et al.   BRITISH JOURNAL OF CANCER

Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer

(2009) D. S. Welsbie et al.   CANCER RESEARCH

TMPRSS2-ERG and PTEN loss in prostate cancer

(2009) Jeremy A Squire   NATURE GENETICS

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

(2008) W Weichert et al.   BRITISH JOURNAL OF CANCER

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

(2008) Maisa Yoshimoto et al.   MODERN PATHOLOGY

Analyzing real-time PCR data by the comparative CT method

(2008) Thomas D Schmittgen et al.   Nature Protocols